Pharmaceutical Lifecycle Management
eBook - ePub

Pharmaceutical Lifecycle Management

Making the Most of Each and Every Brand

Tony Ellery, Neal Hansen

Partager le livre
  1. English
  2. ePUB (adapté aux mobiles)
  3. Disponible sur iOS et Android
eBook - ePub

Pharmaceutical Lifecycle Management

Making the Most of Each and Every Brand

Tony Ellery, Neal Hansen

DĂ©tails du livre
Aperçu du livre
Table des matiĂšres
Citations

À propos de ce livre

A comprehensive guide to optimizing the lifecycle management of pharmaceutical brands

The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they can—and must—do to get the most out of their brands.

Offering a truly immersive introduction to LCM options for pharmaceuticals, the book incorporates numerous real-life case studies that demonstrate successful and failed lifecycle management initiatives, explaining the key takeaway of each example. Filled with practical information on the process of actually writing and presenting an LCM plan, as well as how to link corporate, portfolio, and individual brand strategies, the book also offers a look ahead to predict which LCM strategies will continue to be effective in the future.

While the development of new drugs designed to address unmet patient needs remains the single most important goal of any pharmaceutical company, effective LCM is invaluable for getting the greatest possible value from existing brands. Pharmaceutical Lifecycle Management walks you through the process step by step, making it indispensable reading for pharmaceutical executives and managers, as well as anyone working in the fields of drug research, development, and regulation.

Foire aux questions

Comment puis-je résilier mon abonnement ?
Il vous suffit de vous rendre dans la section compte dans paramĂštres et de cliquer sur « RĂ©silier l’abonnement ». C’est aussi simple que cela ! Une fois que vous aurez rĂ©siliĂ© votre abonnement, il restera actif pour le reste de la pĂ©riode pour laquelle vous avez payĂ©. DĂ©couvrez-en plus ici.
Puis-je / comment puis-je télécharger des livres ?
Pour le moment, tous nos livres en format ePub adaptĂ©s aux mobiles peuvent ĂȘtre tĂ©lĂ©chargĂ©s via l’application. La plupart de nos PDF sont Ă©galement disponibles en tĂ©lĂ©chargement et les autres seront tĂ©lĂ©chargeables trĂšs prochainement. DĂ©couvrez-en plus ici.
Quelle est la différence entre les formules tarifaires ?
Les deux abonnements vous donnent un accĂšs complet Ă  la bibliothĂšque et Ă  toutes les fonctionnalitĂ©s de Perlego. Les seules diffĂ©rences sont les tarifs ainsi que la pĂ©riode d’abonnement : avec l’abonnement annuel, vous Ă©conomiserez environ 30 % par rapport Ă  12 mois d’abonnement mensuel.
Qu’est-ce que Perlego ?
Nous sommes un service d’abonnement Ă  des ouvrages universitaires en ligne, oĂč vous pouvez accĂ©der Ă  toute une bibliothĂšque pour un prix infĂ©rieur Ă  celui d’un seul livre par mois. Avec plus d’un million de livres sur plus de 1 000 sujets, nous avons ce qu’il vous faut ! DĂ©couvrez-en plus ici.
Prenez-vous en charge la synthÚse vocale ?
Recherchez le symbole Écouter sur votre prochain livre pour voir si vous pouvez l’écouter. L’outil Écouter lit le texte Ă  haute voix pour vous, en surlignant le passage qui est en cours de lecture. Vous pouvez le mettre sur pause, l’accĂ©lĂ©rer ou le ralentir. DĂ©couvrez-en plus ici.
Est-ce que Pharmaceutical Lifecycle Management est un PDF/ePUB en ligne ?
Oui, vous pouvez accĂ©der Ă  Pharmaceutical Lifecycle Management par Tony Ellery, Neal Hansen en format PDF et/ou ePUB ainsi qu’à d’autres livres populaires dans Medicine et Pharmacology. Nous disposons de plus d’un million d’ouvrages Ă  dĂ©couvrir dans notre catalogue.

Informations

Éditeur
Wiley
Année
2012
ISBN
9781118265895
Édition
1
Sous-sujet
Pharmacology
INDEX
Abbott
Abbreviated New Drug Applications
ACE-inhibitors. See also names of specific ACE-inhibitors
acetanilide
Acino
AclastaÂź
acne treatments. See also names of specific acne drugs
ACS (acute coronary syndromes). See also names of specific ACS drugs
active ingredients, and generic drugs
active metabolites
active substance, as barrier to entry
ActonelÂź
Actoplus MetÂź
ActosÂź
acute coronary syndromes (ACS). See also names of specific ACS drugs
AD (Alzheimer’s disease). See also names of specific AD drugs
adalimumab
additive effects of fixed-dose combination therapies
AfinitorÂź
age-related macular degeneration (AMD). See also names of specific AMD drugs
AIA (America Invents Act)
AIDS
Alcon
alendronate
aliskiren
Alkermes
Allergan
allergic rhinitis. See also names of specific allergic rhinitis drugs
Altana
Alzheimer’s disease (AD). See also names of specific AD drugs
AMD (age-related macular degeneration). See also names of specific AMD drugs
America Invents Act
Amgen
amlodipine
ANDAs. See Abbreviated New Drug Applications
AndroGelÂź
anemia. See also names of specific anemia drugs
AngeliqÂź
angiotensin receptor blockers (ARBs). See also names of specific ARBs
annual fee for drug companies, and U.S. health-care reform
antacids. See also names of specific antacids
antibiotics. See also names of specific antibiotics
antihistamines. See also names of specific antihistamines
antihypertensives. See hypertension; specific categories and names of antihypertensives
antiplatelet agents. See also names of specific antiplatelet agents
antipsychotic drugs. See also names of specific antipsychotic drugs
antisepsis drugs. See also names of specific antisepsis drugs
antitrust lawsuit, drug retailers and BMS/Sanofi-Aventis
antivascular endothelial growth factor (VEGF) therapy. See also names of specific VEGF inhibitors
AOK
Apotex
approval of drugs
Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
Approved LCM Proposal
AranespÂź
ARBs (angiotensin receptor blockers). See also names of specific ARBs
ArcoxiaÂź
AriceptÂź
aspirin
asthma. See also names of specific asthma drugs
AstraZeneca
and biosimilars development
and generics
and over-the-counter switching
and switch from PrilosecÂź to NexiumÂź
atorvastatin
“at-risk” launche...

Table des matiĂšres